✦ LIBER ✦

Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes

Book ID: 114346666
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 38 KB
Volume: 10
Category: Article
ISSN: 1062-1458
DOI: 10.1016/s1062-1458(01)00370-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of sibrafiban with aspirin fo

Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial

📂 Article 📅 2000 🏛 The Lancet 🌐 English ⚖ 118 KB

Cost Effectiveness of Aspirin, Clopidogr

Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease

✍ Gaspoz, Jean-Michel; Coxson, Pamela G.; Goldman, Paula A.; Williams, Lawrence W. 📂 Article 📅 2002 🏛 Massachusetts Medical Society 🌐 English ⚖ 109 KB

Long-term oral platelet glycoprotein IIb

Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) trial

✍ L.Kristin Newby 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Randomized, Double-blind, Placebo-contro

Randomized, Double-blind, Placebo-controlled Trial of Diazepam, Nitroglycerin, or Both for Treatment of Patients with Potential Cocaine-associated Acute Coronary Syndromes

✍ Brigitte M. Baumann; Jeanmarie Perrone; Sarah E. Hornig; Frances S. Shofer; Judd 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

Prevalence and management of hypertensio

Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: Observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials

✍ Camille G. Frazier; Svati H. Shah; Paul W. Armstrong; Manjushri V. Bhapkar; Darr 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 159 KB

PCV68 COST-EFFECTIVENESS OF GENOTYPE-DRI

PCV68 COST-EFFECTIVENESS OF GENOTYPE-DRIVEN ANTIPLATELET THERAPY FOR SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME

✍ DJ Crespin; JJ Federspiel; AK Biddle; D Jonas; SC Stearns; JS Rossi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB